Genincode PLC
LSE:GENI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Silgan Holdings Inc
F:SL3
|
US |
|
K
|
Kawasaki Heavy Industries Ltd
DUS:KHE
|
JP |
|
B
|
Beijing Baination Pictures Co Ltd
SZSE:300291
|
CN |
|
UP Fintech Holding Ltd
NASDAQ:TIGR
|
CN |
|
S
|
Shanghai HIUV New Materials Co Ltd
SSE:688680
|
CN |
|
Biome Technologies PLC
LSE:BIOM
|
UK |
|
Seiko Epson Corp
TSE:6724
|
JP |
|
Elanor Retail Property Fund
ASX:ERF
|
AU |
|
Kingkey Intelligence Culture Holdings Ltd
HKEX:550
|
HK |
|
NewMarket Corp
NYSE:NEU
|
US |
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| UK |
G
|
Genincode PLC
LSE:GENI
|
8.3m GBP |
Loading...
|
|
| US |
|
CVS Health Corp
NYSE:CVS
|
100.1B USD |
Loading...
|
|
| US |
C
|
Cigna Group
XMUN:CGN
|
69.6B EUR |
Loading...
|
|
| US |
|
Cigna Corp
NYSE:CI
|
73.1B USD |
Loading...
|
|
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
25.2B EUR |
Loading...
|
|
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
23.3B EUR |
Loading...
|
|
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
22.6B USD |
Loading...
|
|
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
21.9B USD |
Loading...
|
|
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
11.2B EUR |
Loading...
|
|
| US |
|
Guardant Health Inc
NASDAQ:GH
|
12.1B USD |
Loading...
|
|
| US |
|
DaVita Inc
NYSE:DVA
|
10.2B USD |
Loading...
|
Market Distribution
| Min | -195 650% |
| 30th Percentile | 0% |
| Median | 0.1% |
| 70th Percentile | 0.2% |
| Max | 4 630.7% |
Other Profitability Ratios
Genincode PLC
Glance View
GENinCode UK Ltd. engages in the risk assessment and prediction of cardiovascular disease. The company is headquartered in Oxford, Oxfordshire. The company went IPO on 2021-07-22. The firm develops patented deoxyribonucleic acid (DNA) risk assessment products which utilize artificial intelligence (AI), bioinformatics and a globally recognized clinical evidence base to provide predictive analysis of a patient’s health risk. The Company’s clinical diagnostic tests cover global disease areas such as cardiovascular, cancer and diabetes.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Genincode PLC is -176.9%, which is above its 3-year median of -268%.
Over the last 3 years, Genincode PLC’s Operating Margin has increased from -451.3% to -176.9%. During this period, it reached a low of -451.3% on Jun 30, 2022 and a high of -176.9% on Jun 30, 2025.
